Skip to main content

Molnupiravir 200 mg

Product Description
  • An oral antiviral drug for emergency treatment of mild to moderate Covid-19 patients.
  • U.S. FDA approved for emergency treatment of adult patients infected with the SARS-CoV-2 (COVID-19) virus and at risk for severe progression.
  • Using Molnovir to treat patients with COVID-19 showed significant clinical outcomes including:
  • The first oral antiviral drug that is directly effective in attenuating viral RNA and SARS-CoV-2 in the nasopharynx.
  • Convenient short-term treatment (5 days).
  • Decreases the risk of hospitalization and mortality in adult patients suffering from mild-to-moderate COVID-19.
  • Reduces patient’s risks of receiving mechanical ventilation.
  • Effective against SARS-CoV-2 variants.
  • Safe and well-tolerated.